AbbVie (NYSE:ABBV) Stock Price Up 1.6% – Here’s Why

AbbVie Inc. (NYSE:ABBV)’s stock price was up 1.6% during trading on Monday. The company traded as high as $281.30 and last traded at $280.8740. Approximately 5,493,473 shares were traded during trading, a decline of 14% from the average session volume of 6,414,131 shares. The stock had previously closed at $276.47.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed that a subcutaneous version of SKYRIZI produced meaningful clinical and endoscopic responses in adults with moderately to severely active Crohn’s disease, with a safety profile consistent with the established treatment. The results could support regulatory review of a more convenient induction option and expand SKYRIZI’s commercial opportunity. AbbVie’s Crohn’s Disease Drug SKYRIZI Shows More Positive Results
• Positive Sentiment: Additional SKYRIZI and RINVOQ inflammatory bowel disease updates, along with expectations for strong growth from Rinvoq, Skyrizi and Vraylar, have improved confidence in AbbVie’s post-Humira revenue drivers. RBC also expects the company to deliver a third-quarter top-line beat. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Erste Group Bank raised its FY2027 EPS forecast for AbbVie to $16.34 from $16.19 and maintained a Buy rating. Several analysts have also remained constructive, including RBC, which reaffirmed an Outperform rating. AbbVie analyst estimate update
• Neutral Sentiment: Analysts and investors remain divided on valuation. Comparisons with Sanofi favor Sanofi because of its upgraded outlook, Dupixent growth and lower valuation, while other analyses argue AbbVie’s recent pipeline wins could make the shares undervalued over the long term. Sanofi or AbbVie comparison
• Negative Sentiment: One recent valuation analysis placed AbbVie’s estimated fair value below the market price, highlighting downside risk if the company’s pipeline or earnings growth fails to meet elevated expectations.
• Neutral Sentiment: An executive sale of AbbVie shares may attract some investor attention, although the available reports do not indicate that it reflects a change in the company’s fundamental outlook.

Analysts Set New Price Targets

ABBV has been the subject of several recent research reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $280.00 price objective on shares of AbbVie in a research report on Tuesday. Cantor Fitzgerald lifted their target price on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Citigroup lifted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group boosted their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, HSBC upped their price target on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Price Performance

The stock’s 50-day simple moving average is $260.41 and its 200 day simple moving average is $237.87. The stock has a market capitalization of $501.03 billion, a P/E ratio of 80.11, a PEG ratio of 1.28 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the business earned $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 13.95 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in the stock. State Street Corp grew its position in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new stake in AbbVie in the 2nd quarter valued at about $2,905,952,000. Deutsche Bank AG lifted its position in shares of AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. Finally, Amundi lifted its position in shares of AbbVie by 2.4% during the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock worth $2,326,728,000 after buying an additional 247,689 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.